UCB - The Bradford Era

Press Releases

UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025

UCB

April 3, 2025

BRUSSELS , April 3, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced it will present 24 abstracts from its expansive neur...

Press Releases

Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome

UCB

March 12, 2025

ATLANTA , March 12, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that Epilepsia published findings from the final ana...

Press Releases

BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

UCB

March 7, 2025

ATLANTA , March 7, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced two-year data from the BE HEARD^ trials for BIMZELX ®...

Press Releases

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB

February 27, 2025

ATLANTA , Feb. 27, 2025 /PRNewswire/ -- UCB Full-Year Report 2024, Brussels ( Belgium ) – regulated information Jean-Christophe Tellier , CEO UCB says...

Press Releases

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

UCB

January 16, 2025

ATLANTA , Jan. 16, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and au...